.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC26_Vorapaxar.Vorapaxar

Information

Vorapaxar is an orally active, selective protease-activated receptor-1 (PAR-1) antagonist used as an antiplatelet agent to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. It is approved for clinical use in several regions including the United States and European Union.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult subjects, both male and female, after oral administration of vorapaxar.

References

1. Chen, X, et al., & Hu, P (2014). Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects. International journal of clinical pharmacology and therapeutics 52(10) 889–899. DOI:10.5414/CP202121 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25138682

Revisions

• 06/2025 initial generated model